39 results on '"Rina Jiromaru"'
Search Results
2. Delayed pharyngocutaneous fistula caused by molecular targeted therapy: a case report
- Author
-
Mioko Matsuo, Kazuki Hashimoto, Rina Jiromaru, and Takashi Nakagawa
- Subjects
Molecular targeted therapy ,Delayed pharyngocutaneous fistula ,Anastomotic leakage ,Adverse events ,Medicine - Abstract
Abstract Background Molecular-targeted agents used as a treatment for cancer can cause some rare and serious adverse events such as, delayed wound healing. Depending on the anticancer drug used, temporary withdrawal may be recommended before and after surgery to avoid complications. Once a surgical incision has healed and closed completely, wounds rarely open because of the initiation of molecular targeted therapy several months to years after surgery. Here, we aimed to describe a rare complication of pharyngocutaneous fistula in two patients that was thought to be caused by molecular targeted therapy. Case presentation Case 1 involved a 64-year-old asian man who developed a delayed pharyngocutaneous fistula 3 months after total laryngectomy for laryngeal cancer. Ramucirumab, a vascular endothelial growth factor receptor inhibitor used for recurrent gastric cancer, was speculated to be involved. Case 2 involved a 71-year-old japanese man who developed a delayed pharyngocutaneous fistula 2 years and 1 month after total pharyngeal laryngectomy for pharyngeal cancer. It was speculated that imatinib, a platelet-derived growth factor receptor alpha inhibitor used for chronic myeloid leukemia, was involved. Conclusions Although the incidence of late drug-induced anastomotic leakage is very low, when it occurs, it makes oral intake impossible for an extended period and interferes with the appropriate cancer treatment. In this report, we demonstrate the details of these two patients with such a rare complication, which may help accumulate essential data on this topic.
- Published
- 2022
- Full Text
- View/download PDF
3. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
- Author
-
Takahiro Wakasaki, Tomomi Manako, Ryuji Yasumatsu, Hirotaka Hara, Satoshi Toh, Muneyuki Masuda, Moriyasu Yamauchi, Yuichiro Kuratomi, Emi Nishimura, Toranoshin Takeuchi, Mioko Matsuo, Rina Jiromaru, Kazuki Hashimoto, Noritaka Komune, and Takashi Nakagawa
- Subjects
Medicine ,Science - Abstract
ObjectivesThe benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration.Materials and methodsWe retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45).ResultsThe objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B.ConclusionAlthough PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended.
- Published
- 2022
- Full Text
- View/download PDF
4. Malignant perivascular epithelioid cell tumor mimicking jugular foramen schwannoma: A case report and literature review
- Author
-
Noritaka Komune, Shogo Masuda, Ryuji Yasumatsu, Takahiro Hongo, Rina Jiromaru, Satoshi Matsuo, Osamu Akiyama, Nana Tsuchihashi, Nozomu Matsumoto, Hidetaka Yamamoto, and Takashi Nakagawa
- Subjects
Oncology ,Surgery ,Cancer surgery ,Neurosurgery ,Ear-Nose-Throat ,Jugular foramen ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Background: Perivascular epithelioid cell tumors (PEComas) of the skull base are extremely rare. Here we report the first description of a malignant PEComa mimicking jugular foramen schwannoma and presenting as Collet-Sicard syndrome, and we review the previous literature on PEComas of the head, neck and skull base. Case description: A 29-year-old woman presented with hoarseness, dysphagia, vomiting, and headache. She was first diagnosed with Collet-Sicard syndrome caused by thrombosis of the sigmoid and transverse sinuses. She was treated with anticoagulant therapy, and the hoarseness and paralysis of the accessory nerve improved. Later, at age 31, the hoarseness again worsened. At another hospital, enhanced computed tomography revealed a tumor in the jugular foramen extending to the neck and medially displacing the internal carotid artery. She was referred to our hospital for further examination and was diagnosed with jugular foramen schwannoma causing thrombosis of the sinuses. At the one-year follow-up, the tumor had grown rapidly and had started to surround the internal carotid artery. We therefore performed a tissue biopsy of the tumor in the jugular foramen and neck. Based on pathological analysis, we made a definitive diagnosis of malignant PEComa. Conclusions: It may be extremely challenging to reach an accurate diagnosis of PEComa in the skull-base region, which can cause a delay in treatment initiation. When atypical clinical features for a skull-base tumor are found, we recommend preliminary biopsy to obtain a definitive diagnosis and initiate an appropriate treatment strategy as early as possible.
- Published
- 2020
- Full Text
- View/download PDF
5. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Author
-
Takahiro Wakasaki, Ryuji Yasumatsu, Muneyuki Masuda, Toranoshin Takeuchi, Tomomi Manako, Mioko Matsuo, Rina Jiromaru, Ryutaro Uchi, Noritaka Komune, Teppei Noda, and Takashi Nakagawa
- Subjects
biomarker ,chemotherapy ,C-reactive protein ,distant metastasis ,head and neck squamous cell carcinoma ,neutrophil to lymphocyte ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.
- Published
- 2020
- Full Text
- View/download PDF
6. Clinical Analysis of Oral Squamous Cell Carcinoma: A Single-institution Experience.
- Author
-
RINA JIROMARU, RYUJI YASUMATSU, MIOKO MATSUO, KAZUKI HASHIMOTO, RYUNOSUKE KOGO, and TAKASHI NAKAGAWA
- Subjects
SQUAMOUS cell carcinoma ,HEAD & neck cancer ,CANCER diagnosis ,ORAL cancer ,OVERALL survival ,PROGNOSIS - Abstract
Background/Aim: There is limited evidence about the significance of head and neck surgical observation at the time of diagnosis and follow-up of oral cancer after treatment. The aim of this study was to elucidate the prognosis and prognostic factors of oral squamous cell carcinoma (OSCC), analyze cases of double cancers, and highlight the importance of examinations during both diagnosis and post-treatment for OSCC. Patients and Methods: We performed a retrospective analysis of 272 OSCC cases treated for the first time during a 10-year period from April 2013 to March 2023 at Kyushu University Hospital. Information obtained in the clinical setting, such as age, stage, prognosis, and presence of double cancers, was used in the analysis. Results: The mean age of 272 patients was 69 years; 203 patients were males and 69 were females. The most common oral cancer sites were the tongue (54.4%). The 5-year overall survival rate was 63.8%. Double cancer was found in 93 patients (34.2%). Synchronous double cancers were found in 38 patients (14.0%), 50% of whose cancer types were head and neck cancers. Conclusion: We analyzed 272 OSCC patients treated at the Kyushu University Hospital, and the results were comparable to those reported by other institutions. Tumor site, age, and stage were identified as prognostic factors. Half of the patients with synchronous double cancers had head and neck cancer, and 3-10% of patients with double cancers after treatment for OSCC also had head and neck cancer, suggesting the importance of otorhinolaryngological observation at the time of the diagnosis and after treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer
- Author
-
Mioko, Matsuo, Shingo, Baba, Kazuki, Hashimoto, Takuro, Isoda, Yoshiyuki, Kitamura, Ryunosuke, Kogo, Rina, Jiromaru, Takahiro, Hongo, Tomomi, Manako, and Takashi, Nakagawa
- Subjects
Cancer Research ,Oncology ,General Medicine - Abstract
Differentiated thyroid cancer (DTC) has a good prognosis, except in the case of patients with radioiodine therapy (RIT)-refractory cancer. However, since DTC is essentially a slowly progressing cancer, it is usually judged to be a DTC with a poor prognosis after multiple RITs and yearly follow-up with echo, computed tomography (CT), and serum thyroglobulin values. This study investigated whether fluorodeoxyglucose-positron emission tomography/CT (FDG PET/CT) combined with initial RIT could identify early-stage patients with poor prognosis.We evaluated 100 patients with high-risk DTC who underwent total thyroidectomy and received RIT at our institution. We analyzed the clinical outcomes of patients andThe 10-year overall survival (OS) was 87.9%, with no significant difference in OS between
- Published
- 2022
8. Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma
- Author
-
KAZUKI HASHIMOTO, RYUJI YASUMATSU, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, HIDEOKI URYU, TORAHIKO NAKASHIMA, AKIHIRO TAMAE, RISA TANAKA, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKAMASA YOSHIDA, and TAKASHI NAKAGAWA
- Subjects
Adult ,Aged, 80 and over ,Male ,Cancer Research ,Carcinoma ,General Medicine ,Middle Aged ,Salivary Gland Neoplasms ,Survival Analysis ,B7-H1 Antigen ,Treatment Outcome ,Oncology ,Humans ,Female ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies - Abstract
The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear.We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The expression of programmed cell death ligand 1 (PD-L1) and mismatch repair (MMR) proteins was also analyzed.The objective response rate (ORR) was 11.1%. The histopathological subtypes of patients who achieved complete response or partial response were salivary duct carcinoma (SDC) in three patients and poorly differentiated carcinoma in one patient, all of whom showed a positive PD-L1 expression. The expression of MMR proteins was not associated with the efficacy of PD-1 inhibitors.Although the efficacy of PD-1 inhibitor therapy in R/M SGC is limited, certain patients may respond and achieve long-term disease control. There is a potential therapeutic effect in SDC patients with positive PD-L1 expression.
- Published
- 2022
9. A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution’s experience
- Author
-
Rina Jiromaru, Ryuji Yasumatsu, Hidetaka Yamamoto, Ryosuke Kuga, Takahiro Hongo, Takafumi Nakano, Tomomi Manako, Kazuki Hashimoto, Takahiro Wakasaki, Mioko Matsuo, and Takashi Nakagawa
- Subjects
Otorhinolaryngology ,General Medicine - Published
- 2022
10. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer
- Author
-
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, HIDEOKI URYU, TORAHIKO NAKASHIMA, AKIHIRO TAMAE, RISA TANAKA, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKAMASA YOSHIDA, and TAKASHI NAKAGAWA
- Subjects
Pharmacology ,Cancer Research ,Antineoplastic Combined Chemotherapy Protocols ,Cetuximab ,Humans ,Fluorouracil ,Cisplatin ,Neoplasm Recurrence, Local ,Salivary Gland Neoplasms ,General Biochemistry, Genetics and Molecular Biology ,Carboplatin ,Retrospective Studies ,Research Article - Abstract
Background/Aim: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). Patients and Methods: We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis. Results: EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases. Conclusion: Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.
- Published
- 2022
11. Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years
- Author
-
MIOKO MATSUO, RYUJI YASUMATSU, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, TAKAHIRO WAKASAKI, KAZUKI HASHIMOTO, RINA JIROMARU, TOMOMI MANAKO, and TAKASHI NAKAGAWA
- Subjects
Pharmacology ,Cancer Research ,Antineoplastic Agents, Immunological ,Nivolumab ,Head and Neck Neoplasms ,Squamous Cell Carcinoma of Head and Neck ,Carcinoma ,Humans ,Neoplasm Recurrence, Local ,General Biochemistry, Genetics and Molecular Biology ,Research Article ,Follow-Up Studies ,Retrospective Studies - Abstract
Background/Aim: A long-term effect has been confirmed in clinical practice since the introduction of nivolumab for treating various malignant tumors. A similar phenomenon is speculated to occur in head and neck cancer; however, details remain unclear due to the lack of long-term reports. We aimed to investigate the five-year outcomes in long-term responders for over two years, and evaluate the optimal duration of therapy with nivolumab. Patients and Methods: In this retrospective observational study, we analyzed 203 cases of recurrent/metastatic head and neck squamous cell carcinoma (R/MHNSCC), including 33 long-term responders. Results: The median overall survival (OS), 5-year OS, median progression-free survival (PFS), and 5-year PFS values in the 203 cases were 13.1 months, 19.2%, 3.1 months, and 13.2%, respectively. Of the 33 long-term responders, 14 (42.4%) continued using nivolumab for more than 2 years. The remaining 19 patients (57.6%) discontinued nivolumab. The most common reason for discontinuation was severe immune-related adverse events (irAEs) (9 cases; 27.3%); in these 9 cases, the median disease-free survival was 33.2 (range=10.7-44.3) months. Nine patients (21.2%) were considered to have progressive disease (PD) after at least 2 years of administration, and 3 patients (9.1%) requested to discontinue treatment because a complete response (CR) was achieved. Conclusion: This study demonstrated the durable and long-term benefit of nivolumab in R/MHNSCC. In the future, we aim to accumulate real-world data for the establishment of criteria for completion of nivolumab treatment in long-term responders.
- Published
- 2022
12. HPV Infection in Squamous Cell Carcinoma of the Hypopharynx, Larynx, and Oropharynx With Multisite Involvement.
- Author
-
Ryosuke Kuga, Hidetaka Yamamoto, Rina Jiromaru, Takahiro Hongo, Ryuji Yasumatsu, Mioko Matsuo, Kazuki Hashimoto, Midori Taniguchi, Takashi Nakagawa, and Yoshinao Oda
- Published
- 2023
- Full Text
- View/download PDF
13. Pembrolizumab Monotherapy Versus Pembrolizumab Plus Chemotherapy in Patients With Head and Neck Squamous Cell Carcinoma.
- Author
-
MIOKO MATSUO, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, MASAHIKO TAURA, KAZUKI HASHIMOTO, RYUNOSUKE KOGO, RINA JIROMARU, TAKAHIRO HONGO, TOMOMI MANAKO, and TAKASHI NAKAGAWA
- Subjects
HEAD & neck cancer ,PEMBROLIZUMAB ,SQUAMOUS cell carcinoma ,CANCER chemotherapy ,ADVERSE health care events - Abstract
Background/Aim: Pembrolizumab monotherapy and pembrolizumab with chemotherapy (combination therapy) are standard treatments for recurrent and metastatic head and neck squamous cell carcinoma (R/M-HNSCC). This study aimed to explore which of the two, pembrolizumab monotherapy or combination therapy is superior for long-term use. Patients and Methods: Participants of the study were 139 patients with histologically confirmed squamous cell carcinoma who had been treated with pembrolizumab monotherapy or combination therapy at the Kyushu University and related facilities. We analysed differences regarding longterm survival rate and adverse events (AEs) between the pembrolizumab monotherapy and combination therapy groups. Results: The overall 2-year progression-free survival and 2-year overall survival were 28.6% and 41.8%, respectively; these results were not significantly different between the two groups. Patients in the monotherapy group with AEs had a significantly better prognosis than those without AEs (in both the monotherapy and combination therapy groups). In the combination therapy group, there was no difference in prognosis between those with AEs and those without AEs (p=0.636). Conclusion: Considering the treatment of R/M-HNSCC from a long-term perspective, we identified that it is better to use pembrolizumab as monotherapy than to use it in combination with chemotherapy. Combination therapy did not improve prognosis; moreover, it can also cause additional adverse effects. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies.
- Author
-
MIOKO MATSUO, KAZUKI HASHIMOTO, RYUNOSUKE KOGO, RINA JIROMARU, TAKAHIRO HONGO, TOMOMI MANAKO, and TAKASHI NAKAGAWA
- Subjects
HEAD & neck cancer ,CANCER genetics ,DRUG administration ,IMMUNE checkpoint inhibitors ,GENETIC mutation - Abstract
Background/Aim: In recent years, individual patient cancer genomic profiling (CGP) has become more accessible, allowing determination of therapeutic strategies using driver gene mutations in cancer therapy. However, this precision oncology approach, tailored to specific patients, remains experimental. In this study, we verified the feasibility and benefit of using CGP to guide treatment of malignant head and neck tumors. We aimed to evaluate the profiling and clinical courses of patients with head and neck malignancies who underwent CGP and determine the extent to which CGP for head and neck malignancies has resulted in beneficial drug administration. Patients and Methods: We analyzed CGP results, prognosis, and drug administration status in 27 patients. These patients had completed (or were expected to complete) standard therapy or had rare cancers without standard therapy. Results: At least one somatic actionable gene alteration was seen in 25 (92.6%) patients, with a median number of actionable alterations per patient of 4 (range=0-11). Drugs in clinical trials were recommended to 22 (81.5%) patients, but none could participate. However, 3 patients (11.1%) could use approved drugs off-label based on CGP results. The most common genetic abnormality was TP53 (66.7%), with TP53 mutations leading to poor prognosis. Conclusion: CGP is clinically useful and serves as a bridge to increase the number of therapeutic options. However, candidate drugs confirmed using CGP may be ineffective when administered. Therefore, oncologists should not blindly accept CGP therapeutic recommendations but should make recommendations that lead to optimal therapies after proper verification. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options
- Author
-
Rina Jiromaru, Takashi Nakagawa, and Ryuji Yasumatsu
- Subjects
Oncology - Abstract
Nasopharyngeal carcinoma (NPC) has seen improved treatment outcomes and a decrease in incidence worldwide in recent years due to developments in medicine and improved public health. However, 70% of cases are still diagnosed at advanced stages and these advanced NPC cases show a poor prognosis. Reports on current and future treatment in advanced NPC are summarized. Chemoradiotherapy is the mainstay of treatment for advanced NPC. The administration of platinum agents as a concurrent drug and intensity modulated radiotherapy (IMRT) is the most appropriate irradiation method, and is associated with high local control rates. For induction and adjuvant chemotherapy, platinum-based two- or three-drug combination chemotherapy is recommended. The tumour volume, plasma Epstein-Barr virus (EBV)-DNA levels, and the tumour site are used to determine the indication for adjuvant and neo-adjuvant chemotherapy. The tolerability of induction chemotherapy is controversial, and the indications and timing should be carefully considered in each case. Chemotherapy is used for patients with distant metastasis. Gemcitabine/cisplatin is the first-line regimen. The efficacy of immune checkpoint inhibitor (ICI) treatment has recently been reported for NPC and, as in other areas of the head and neck, it is expected to be effective for patients with recurrent/distant metastasis. Trials are underway for various uses of ICIs, including induction chemotherapy, postoperative treatment, and use in combination with chemoradiotherapy. Immunotherapy for NPC, an EBV-associated cancer, has been reported to have some efficacy with immunotherapy used in other EBV-associated cancers. Immunotherapy may be introduced for NPC in the future, depending on the results of clinical trials. Future changes in the treatment of NPC are expected to include risk classification based on plasma EBV-DNA levels and the development of personalized treatment with individual selection of timing and type of therapy.
- Published
- 2022
16. p16 overexpression and Rb loss correlate with high‐risk HPV infection in oropharyngeal squamous cell carcinoma
- Author
-
Rina Jiromaru, Ryuji Yasumatsu, Kazuki Hashimoto, Yui Nozaki, Yoshinao Oda, Takahiro Hongo, Takafumi Nakano, Hidetaka Yamamoto, and Takashi Nakagawa
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Histology ,Combined use ,Retinoblastoma Protein ,Gastroenterology ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Partial loss ,Biomarkers, Tumor ,Overall survival ,Humans ,Medicine ,Oropharyngeal squamous cell carcinoma ,Papillomaviridae ,Cyclin-Dependent Kinase Inhibitor p16 ,In Situ Hybridization ,Aged ,Retrospective Studies ,Aged, 80 and over ,Human papillomavirus 16 ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Surrogate endpoint ,Papillomavirus Infections ,General Medicine ,Middle Aged ,Immunohistochemistry ,Predictive value ,Oropharyngeal Neoplasms ,030104 developmental biology ,Head and Neck Neoplasms ,High risk hpv ,030220 oncology & carcinogenesis ,Female ,business - Abstract
AIMS p16 is a sensitive surrogate marker for transcriptionally active high-risk human papillomavirus (HR-HPV) infection in oropharyngeal squamous cell carcinoma (OPSCC), but it is not sufficient in all clinical settings. METHODS AND RESULTS We examined the p16 and Rb expression status in 177 OPSCC cases by immunohistochemistry and the presence of transcriptionally active HR-HPV infection by mRNA in-situ hybridisation. The 177 cases were divided into p16+ /HPV+ (n = 105, 59.3%), p16+ /HPV- (n = 8, 4.5%) and p16- /HPV- (n = 64, 36.2%) groups. The p16+ /HPV- and p16- /HPV- groups had a trend towards worse overall survival (OS) or significantly worse OS than the p16+ /HPV+ group (n = 105) (P = 0.0610, P = 0.0004, respectively). We divided the Rb status into preserved expression (> 90%, n = 68), partial loss (PL) (10-90%, n = 97) and complete loss (CL) (
- Published
- 2021
17. Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights.
- Author
-
TAKAHIRO WAKASAKI, RYUJI YASUMATSU, MIKA TANABE, HIROSHI YOSHIKAWA, RINA JIROMARU, KAZUKI HASHIMOTO, MIOKO MATSUO, AKIKO FUJIMURA, and TAKASHI NAKAGAWA
- Subjects
BENIGN tumors ,HEALTH outcome assessment ,CARCINOMA ,POSTOPERATIVE care ,IMMUNE checkpoint inhibitors - Abstract
Background/Aim: Lacrimal sac tumors are rare tumor types, with a long time interval from disease onset to diagnosis. We aimed to investigate the characteristics and outcomes of patients with lacrimal sac tumors. Patients and Methods: The medical records of 25 patients with lacrimal sac tumors initially treated at the Kyushu university hospital from January 1996 to July 2020 were reviewed. Results: Our analysis included 3 epithelial benign tumors (12.0%) and 22 malignant (88.0%) tumors (squamous cell carcinoma, n=6; adenoid cystic carcinoma, n=2; sebaceous adenocarcinoma, n=2; mucoepidermoid carcinoma, n=1; malignant lymphoma, n=10). The average time from symptom onset to diagnosis was 14.7 months (median=8 months; range=1-96 months). The analysis of patients revealed that lacrimal sac mass (22/25, 88.0%) was the most frequent symptom and a possible tumor marker. Most epithelial benign (n=3) and malignant epithelial (n=12) tumors were treated surgically (14/15, 93.3%). One malignant case was treated with heavy ion beam therapy. Eight patients were treated with postoperative (chemo)radiation therapy because of positive surgical margins (including one unanalyzed case). Local control was ultimately achieved in all but one case. The patient survived for 24 months with immune checkpoint inhibitors and subsequent chemotherapy for local and metastatic recurrence. Conclusion: We report our experience in the diagnosis and treatment of lacrimal sac tumors and analyze the clinical trends in cases involving these tumors. Postoperative radiotherapy and pharmacotherapy, including immune checkpoint inhibitors, may be useful for recurrent cases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
- Author
-
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, and TAKASHI NAKAGAWA
- Subjects
Cancer Research ,Antineoplastic Agents, Immunological ,Lung Neoplasms ,Oncology ,Head and Neck Neoplasms ,Humans ,General Medicine ,Antibodies, Monoclonal, Humanized ,Retrospective Studies - Abstract
This study investigated the effectiveness of pembrolizumab with or without chemotherapy on advanced-stage head and neck cancer (HNC), including nasopharyngeal, sinonasal cavity and external auditory canal cancer, in a real-world setting.We retrospectively collected data from 97 HNC patients who were treated with pembrolizumab alone (n=60) or with chemotherapy (n=37), and we investigated the association between clinicopathological findings and treatment response or prognosis.Patients treated with pembrolizumab and chemotherapy had a 1-year overall survival (OS) of 72.8%, objective response rate (ORR) of 48.6%, and serious (≥G3) adverse events (AEs) of 29.7%. Patients treated with pembrolizumab alone had a 1-year OS of 51.9%, ORR of 21.7%, and ≥G3 AEs of 6.7%. Both the ORR and disease control rate (DCR) in the pembrolizumab with chemotherapy group were significantly better than those in the pembrolizumab group (p=0.074 and p=0.00101, respectively). Among patients with distant metastasis, patients on pembrolizumab with chemotherapy achieved significantly better OS than pembrolizumab alone (p=0.0039). Among patients in the pembrolizumab group, both AE-positive and better performance status were associated with longer OS (p=0.011 and p=0.0037, respectively).Our real-world experience reinforces the durability and effectiveness of pembrolizumab for HNC patients. Additionally, our results suggest that pembrolizumab with chemotherapy might be recommended for patients with distant metastasis and no prior treatment. Further studies are needed to determine the optimal treatment strategy for HNC.
- Published
- 2022
19. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma
- Author
-
Rina Jiromaru, Yui Nozaki, Takahiro Hongo, Takafumi Nakano, Azusa Sugii, Masanobu Sato, Minako Fujiwara, Hidetaka Yamamoto, Kenichi Taguchi, Kazuki Hashimoto, and Yoshinao Oda
- Subjects
Adult ,0301 basic medicine ,Adolescent ,Oncogene Proteins, Fusion ,Breast Neoplasms ,Tropomyosin ,Biology ,Pathology and Forensic Medicine ,Fusion gene ,Young Adult ,03 medical and health sciences ,Exon ,0302 clinical medicine ,Proto-Oncogene Proteins ,Biomarkers, Tumor ,ROS1 ,medicine ,Humans ,Child ,Aged ,Gene Rearrangement ,medicine.diagnostic_test ,Carcinoma ,Proto-Oncogene Proteins c-ret ,Receptor Protein-Tyrosine Kinases ,Gene rearrangement ,Middle Aged ,Protein-Tyrosine Kinases ,Salivary Gland Neoplasms ,Immunohistochemistry ,Molecular biology ,ETV6 ,030104 developmental biology ,030220 oncology & carcinogenesis ,Trk receptor ,Female ,Fluorescence in situ hybridization - Abstract
Salivary secretory carcinoma (SASC) is frequently associated with ETV6-neurotrophic tyrosine receptor kinase (NTRK) 3 fusion and more rarely with RET, MET, or ALK rearrangement. We aimed to elucidate the potential diagnostic utility of pan-tropomyosin receptor kinase (Trk) immunohistochemistry and its relationship with the fusion gene subtype in SASC. We examined 33 cases of SASC for immunoexpression of pan-Trk, ALK and ROS1, and gene rearrangement of the ETV6, NTRK3, and RET genes using fluorescence in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR). Thirty (90.9%) of 33 SASCs harbored ETV6-NTRK3 fusion gene transcripts by RT-PCR and/or both ETV6 and NTRK3 gene rearrangements by FISH, and 3 cases (9.1%) had RET gene rearrangement. Most NTRK3-rearranged SASCs (27/33 cases; 81.8%) had conventional ETV6 exon 5-NTRK3 exon 15 fusion, whereas 2 cases (6.1%) had both the conventional fusion and a novel ETV6 exon 4-NTRK3 exon 15 fusion variant. In the remaining one case (3%), only FISH revealed both ETV6 and NTRK3 rearrangements, suggesting an ETV6-NTRK3 fusion with an as yet undetermined break point. All 30 SASCs with ETV6-NTRK3 fusion and/or NTRK3 rearrangement showed nuclear and cytoplasmic immunoreactivity for pan-Trk. In contrast, 3 SASCs with RET rearrangement showed negative or only weak cytoplasmic staining for pan-Trk. There was no case harboring ALK and ROS1 rearrangements. All 17 non-SASC tumors were negative for pan-Trk. The results suggest that nuclear and cytoplasmic immunoreactivity for pan-TRK may be helpful to identify ETV6-NTRK3-fused SASCs and to distinguish them from RET-rearranged SASCs and morphological mimics.
- Published
- 2021
20. High-risk HPV-related Squamous Cell Carcinoma in the Conjunctiva and Lacrimal sac: Clinicopathologic Characteristics and Diagnostic Utility of p16 and Rb Immunohistochemistry
- Author
-
Takahiro Hongo, Hidetaka Yamamoto, Mika Tanabe, Ryuji Yasumatsu, Ryosuke Kuga, Yoshiko Miyazaki, Rina Jiromaru, Kazuki Hashimoto, Yuki Tateishi, Koh-Hei Sonoda, Takashi Nakagawa, and Yoshinao Oda
- Subjects
Papillomavirus Infections ,Immunohistochemistry ,Pathology and Forensic Medicine ,Head and Neck Neoplasms ,DNA, Viral ,Biomarkers, Tumor ,Carcinoma, Squamous Cell ,Humans ,Surgery ,Anatomy ,Conjunctiva ,Nasolacrimal Duct ,Papillomaviridae ,Cyclin-Dependent Kinase Inhibitor p16 ,Retrospective Studies - Abstract
High-risk human papillomavirus (HPV) infection in conjunctival and lacrimal sac squamous cell carcinomas (SCCs) has been sporadically reported; however, its prevalence, clinicopathologic significance and surrogate markers have not been fully elucidated. Here, we attempted to clarify these questions in Japanese patients with conjunctiva and lacrimal sac SCCs. We retrospectively collected 51 conjunctival SCC and 7 lacrimal sac SCC samples and analyzed them for (1) transcriptionally active high-risk HPV infection using messenger RNA in situ hybridization and (2) protein expressions of p16 and Rb using immunohistochemistry (IHC). Among a total of 58 cases, 25 (43.1%) and 16 (27.6%) tumors were positive for p16-IHC and HPV in situ hybridization, respectively. Ten (19.6%) of the 51 conjunctival SCCs, especially in the palpebral conjunctiva, and 6 (85.7%) of the 7 lacrimal sac SCCs were positive for high-risk HPV. High-risk HPV infection was significantly associated with younger patients, nonkeratinizing SCC histology, p16-positivity and partial loss of Rb expression, but not with recurrence risk. Notably, p16-IHC was not a perfect surrogate marker for high-risk HPV infection; only 64% (16/25) of p16-positive tumors were positive for high-risk HPV. In contrast, the p16+/Rb partial loss pattern was exclusively correlated with high-risk HPV-positivity. The results suggest that the combination of p16 and Rb expression patterns by IHC could be a useful method to predict high-risk HPV infection in conjunctival and lacrimal sac SCCs. HPV infection may be of less prognostic value in this field of cancers.
- Published
- 2022
21. Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma
- Author
-
Kenichi Taguchi, Muneyuki Masuda, Yui Nozaki, Azusa Sugii, Ryuji Yasumatsu, Rina Jiromaru, Kazuki Hashimoto, Takahiro Hongo, Hidetaka Yamamoto, Reiko Yoneda, Yoshinao Oda, and Takashi Nakagawa
- Subjects
Adult ,Male ,0301 basic medicine ,DNA Copy Number Variations ,Chromogenic in situ hybridization ,In situ hybridization ,Gene mutation ,medicine.disease_cause ,Pathology and Forensic Medicine ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,symbols.namesake ,Exon ,0302 clinical medicine ,medicine ,Humans ,Copy-number variation ,Aged ,Retrospective Studies ,Aged, 80 and over ,Sanger sequencing ,business.industry ,Papillomavirus Infections ,HPV infection ,Middle Aged ,medicine.disease ,ErbB Receptors ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Carcinoma, Squamous Cell ,Cancer research ,symbols ,Female ,Surgery ,KRAS ,Anatomy ,business ,Paranasal Sinus Neoplasms - Abstract
Sinonasal squamous cell carcinoma (SNSCC) is sometimes associated with high-risk human papillomavirus (HR-HPV) infection and inverted sinonasal papilloma or oncocytic sinonasal papilloma. Frequent mutations of EGFR and KRAS are reported in inverted sinonasal papilloma-related sinonasal squamous cell carcinoma (ISP-SCC) and oncocytic sinonasal papilloma-related SNSCC, respectively. Here, we attempted to determine the prevalence and the prognostic significances of these alterations in SNSCC. We retrospectively collected 146 SNSCCs, including 14 ISP-SCCs, and comprehensively analyzed the HR-HPV infection by human papillomavirus (HPV)-RNA in situ hybridization, EGFR gene copy number gain (CNG) by chromogenic in situ hybridization, and gene mutations in EGFR and KRAS by Sanger sequencing. HR-HPV was detected in 11 cases (7.5%), whereas all 14 ISP-SCCs were negative. EGFR mutations were present in 21 (14.7%) of 143 SNSCCs, including 13/14 (92.9%) ISP-SCCs and 8/129 (6.2%) non-ISP-SCCs (P
- Published
- 2020
22. A clinical analysis of sinonasal squamous cell carcinoma: a comparison of de novo squamous cell carcinoma and squamous cell carcinoma arising from inverted papilloma
- Author
-
Ryuji Yasumatsu, Takahiro Hongo, Ryutaro Uchi, Masahiko Taura, Rina Jiromaru, Takashi Nakagawa, Mioko Matsuo, and Takahiro Wakasaki
- Subjects
Human papilloma virus ,Pathology ,medicine.medical_specialty ,P16 immunohistochemistry ,Clinical pathology ,business.industry ,Inverted papilloma ,General Medicine ,Aggressive disease ,medicine.disease ,stomatognathic diseases ,Rare tumor ,Otorhinolaryngology ,Medicine ,Basal cell ,business ,neoplasms - Abstract
Background: Sinonasal squamous cell carcinoma (SCC) is a rare tumor arising either de novo or in association with inverted papillomas (IPs).Objectives: The aim of this study was to investigate and compare the oncological features and prognosis of patients with sinonasal SCCs based on their etiology.Material and methods: The medical records of 117 patients who had been diagnosed with de novo SCC or those arising from IP (IP-SCC) were retrospectively reviewed. In situ hybridization analyses to detect HPV 16/18DNA and p16 immunohistochemistry were also performed in 10 cases with IP-SCC.Results: The three-year disease-specific survival (DSS) rate was higher in cases with T1, 2 and 3 than in cases with T4 in both tumor groups. T4 cases with de novo SCC had a better DSS than those with IP-SCCs. HPV16/18 was not detected in any of the 10 IP-SCCs.Conclusions and significance: T4 cases with de novo SCC tended to have a better DSS than those with IP-SCC. Since some T4 patients with IP-SCC were found to have a highly aggressive disease, careful treatment planning should be performed. High-risk HPV may not play a vital role in the carcinomatous transformation of most IP-SCC cases.
- Published
- 2020
23. HPV-related Sinonasal Carcinoma
- Author
-
Rina Jiromaru, Takahiro Hongo, Takashi Nakagawa, Yui Nozaki, Kazuki Hashimoto, Muneyuki Masuda, Yoshinao Oda, Kenichi Taguchi, Hidetaka Yamamoto, and Ryuji Yasumatsu
- Subjects
Adult ,Male ,0301 basic medicine ,DNA Copy Number Variations ,Chromogenic in situ hybridization ,In situ hybridization ,Retinoblastoma Protein ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Biomarkers, Tumor ,Carcinoma ,Humans ,Medicine ,Copy-number variation ,Epidermal growth factor receptor ,EGFR Protein Overexpression ,Cyclin-Dependent Kinase Inhibitor p16 ,Aged ,Retrospective Studies ,Aged, 80 and over ,biology ,business.industry ,Genes, p16 ,Papillomavirus Infections ,HPV infection ,Reproducibility of Results ,virus diseases ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,ErbB Receptors ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Cancer research ,biology.protein ,Female ,Surgery ,Anatomy ,business ,Paranasal Sinus Neoplasms ,Follow-Up Studies - Abstract
The prevalence and prognostic value of human papillomavirus (HPV) infection and epidermal growth factor receptor (EGFR) alteration in sinonasal squamous cell carcinoma (SNSCC) are not known. The reliability of p16 overexpression as a surrogate for HPV infection in SNSCC is also unclear. We investigated the prognostic and diagnostic significances of HPV infection, EGFR alteration, and p16 expression in SNSCC. We analyzed high-risk HPV infection by HPV-RNA in situ hybridization and EGFR gene copy number gain (CNG) by chromogenic in situ hybridization and by determining the protein expressions of p16, Rb, and EGFR by immunohistochemistry in 101 SNSCC cases. HPV infection (n=9, 8.9%) and p16 overexpression (n=15, 14.9%) were associated with better overall survival (P=0.0042 and 0.005, respectively). The HPV cases were located predominantly at the nasal cavity with nonkeratinizing histology and partial loss of Rb. Notably, 40% (6/15) of p16 SNSCCs were HPV. Two of these cases showed complete loss of Rb expression by immunohistochemistry, suggesting a reason for the above discrepancy. EGFR CNG, detected in 30.5% of the SNSCCs, was correlated with EGFR protein overexpression (P=0.0001). HPV infection and EGFR CNG were mutually exclusive. The HPV/EGFR CNG group had significantly better overall survival than the HPV/EGFR CNG and HPV/EGFR CNG groups (P=0.0471 and 0.0343, respectively). Our results suggest that HPV infection is a favorable prognostic marker in SNSCC, but p16 is not a perfect surrogate marker; the Rb expression pattern may improve the diagnostic accuracy. The molecular subclassification of SNSCCs based on HPV infection and EGFR copy number status might provide important information for therapeutic strategies.
- Published
- 2019
24. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy
- Author
-
MIOKO MATSUO, RYUJI YASUMATSU, MUNEYUKI MASUDA, SATOSHI TOH, TAKAHIRO WAKASAKI, KAZUKI HASHIMOTO, RINA JIROMARU, TOMOMI MANAKO, and TAKASHI NAKAGAWA
- Subjects
Pharmacology ,Inflammation ,Cancer Research ,Squamous Cell Carcinoma of Head and Neck ,Prognosis ,General Biochemistry, Genetics and Molecular Biology ,Antineoplastic Agents, Immunological ,Nivolumab ,Head and Neck Neoplasms ,Humans ,Lymphocytes ,Neoplasm Recurrence, Local ,Biomarkers ,Retrospective Studies ,Research Article - Abstract
Background/Aim: The inflammation-based prognostic score (IBPS) has attracted attention recently as a prognostic biomarker for head and neck cancer patients. However, as the IBPS often changes after anticancer drug therapy, its independent prognostic value remains controversial. We aimed to investigate the relationship between the IBPS and prognosis in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with nivolumab, and investigate changes in the IBPS before and after nivolumab treatment. Patients and Methods: Total of 164 patients with RMHNSCC received nivolumab therapy were retrospectively analyzed. Results: Univariate analysis among the 164 patients revealed that the performance status (PS), immune-related adverse event (irAE) status, pre- and post-therapy Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and post-eosinophil count, were all significant predictors of overall survival (OS) (p
- Published
- 2021
25. A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience
- Author
-
Rina, Jiromaru, Ryuji, Yasumatsu, Hidetaka, Yamamoto, Ryosuke, Kuga, Takahiro, Hongo, Takafumi, Nakano, Tomomi, Manako, Kazuki, Hashimoto, Takahiro, Wakasaki, Mioko, Matsuo, and Takashi, Nakagawa
- Subjects
Male ,Squamous Cell Carcinoma of Head and Neck ,Papillomavirus Infections ,Alphapapillomavirus ,Middle Aged ,Prognosis ,Oropharyngeal Neoplasms ,Head and Neck Neoplasms ,Carcinoma, Squamous Cell ,Humans ,Female ,RNA, Messenger ,Papillomaviridae ,Cyclin-Dependent Kinase Inhibitor p16 ,Retrospective Studies - Abstract
We herein report the treatment outcome of oropharyngeal squamous cell carcinoma (OPSCC) at Kyushu University Hospital, the total number of OPSCC cases, and changes in the proportion of human papilloma virus (HPV)-related carcinomas over time.We performed a retrospective analysis of 237 cases treated for OPSCC at Kyushu University Hospital between 2013 and 2019. We performed HPV-mRNA in situ hybridization and p16 immunohistochemistry.This study included 197 males (82.1%) and 40 females (17.9%). The disease-specific, progression-free and overall survival (OS) were 69%, 62% and 61%, respectively, over the decade-long study period. p16-Immunohistochemistory and highrisk HPV mRNA in situ hybridization were positive in 114 (48.1%) and 105 (44.3%) cases, respectively. The number of HPV-related OPSCC cases increased according to an annual analysis. HPVThe frequency of HPV-related OPSCC cases is increasing in Japan as well as worldwide, and such cases are characterized by no smoking habit, a young age, and a good prognosis. Even in p16
- Published
- 2021
26. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma
- Author
-
Mioko Matsuo, Rina Jiromaru, Muneyuki Masuda, Takashi Nakagawa, Hidetaka Yamamoto, Ryuji Yasumatsu, Kenichi Taguchi, Kazuki Hashimoto, Satoshi Toh, Yui Nozaki, Takahiro Wakasaki, Akihiro Tamae, Ryosuke Kuga, Yoshinao Oda, and Takahiro Hongo
- Subjects
Oncology ,Male ,Pathology ,medicine.medical_specialty ,DNA Copy Number Variations ,DNA Mismatch Repair ,B7-H1 Antigen ,Pathology and Forensic Medicine ,Proto-Oncogene Proteins p21(ras) ,Lymphocytes, Tumor-Infiltrating ,Internal medicine ,Medicine ,Humans ,Epidermal growth factor receptor ,In Situ Hybridization ,Retrospective Studies ,Cluster of differentiation ,biology ,business.industry ,Tumor-infiltrating lymphocytes ,Papillomavirus Infections ,HPV infection ,Microsatellite instability ,Middle Aged ,medicine.disease ,Immunohistochemistry ,ErbB Receptors ,Mutation ,biology.protein ,Carcinoma, Squamous Cell ,DNA mismatch repair ,Female ,business ,CD8 ,Paranasal Sinus Neoplasms - Abstract
The antitumor efficacies of immune checkpoint inhibitors (ICIs) and the usefulness of potential predictive markers such as programmed death-ligand 1 (PD-L1) expression, density of tumor-infiltrating lymphocytes (TILs) and microsatellite instability (MSI) in sinonasal squamous cell carcinoma (SNSCC) have not been fully elucidated. We retrospectively analyzed 131 SNSCCs with immunohistochemistry for PD-L1 expression, TIL subpopulations and loss of mismatch repair (MMR) proteins as a surrogate for MSI-high. We also comprehensively evaluated the mutual relationships among these immuno-markers, high-risk human papillomavirus (HPV) infection, epidermal growth factor receptor (EGFR) gene status, and KRAS mutation. PD-L1 expression (tumor proportion score ≥ 1%) was detected in 60 (45.8%) SNSCC cases and was significantly associated with worse overall survival (OS) (p = 0.0240). High density of cluster of differentiation 8 (CD8)-positive TILs was significantly associated with better progression-free survival (PFS) (p = 0.0368), and high density of forkhead box protein P3-positive TILs was significantly associated with better PFS and OS (p = 0.0007 and 0.0143, respectively). With respect to the combination of CD8 + TIL and PD-L1 expression, the high-CD8/PD-L1-negative group showed the most favorable prognosis, whereas the low-CD8/PD-L1-positive group showed the worst prognosis. MMR loss was detected in 3 (2.3%) of the 131 cases. HPV infection (6.1%), EGFR mutation (14.5%), EGFR copy number gain (26%), and MMR loss were essentially mutually exclusive; patients in these molecular groups showed significant differences in prognosis but not in the degree of PD-L1 expression or TILs. Among the nine ICI-treated patients, three (33.3%) were responders, and the EGFR-wild type cases (n = 7) showed better clinical responses to an ICI compared to the EGFR-mutant cases (n = 2). Among the patients with residual/recurrent EGFR-wild type tumors (n = 43), ICI treatment significantly improved OS (p = 0.0281). The results suggest that the evaluation of immuno-markers and molecular subclassification may be helpful for prognostic prediction and selecting an individualized therapeutic strategy for patients with SNSCC.
- Published
- 2021
27. Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma
- Author
-
Ryutaro Uchi, Takashi Nakagawa, Tomomi Manako, Takahiro Hongo, Takahiro Wakasaki, Hidetaka Yamamoto, Kuniaki Sato, Mioko Matsuo, Kazuki Hashimoto, Rina Jiromaru, and Ryuji Yasumatsu
- Subjects
Male ,Cancer Research ,Inverted papilloma ,Gene Expression ,Biology ,Polymorphism, Single Nucleotide ,Malignant transformation ,CDKN2A ,medicine ,Carcinoma ,Biomarkers, Tumor ,Humans ,Epidermal growth factor receptor ,neoplasms ,Aged ,Aged, 80 and over ,Papilloma, Inverted ,integumentary system ,High-Throughput Nucleotide Sequencing ,General Medicine ,Genomics ,Oncogenes ,Amplicon ,Middle Aged ,medicine.disease ,FLT4 ,Immunohistochemistry ,stomatognathic diseases ,Oncology ,Mutation ,Cancer research ,biology.protein ,Carcinoma, Squamous Cell ,Papilloma ,Female ,Paranasal Sinus Neoplasms - Abstract
Background The genetic basis of sinonasal inverted papilloma (SNIP)-derived squamous cell carcinoma (SCC) has not yet been well characterized. Aim To characterize the genetic abnormalities of SNIP and SNIP-derived SCC and to uncover their differences. Materials and methods Mutations of 409 genes were analyzed using amplicon targeted sequencing in a total of six papilloma/carcinoma samples from four patients with SNIP-derived SCC. Results The genes that were mutated in multiple cases were epidermal growth factor receptor (EGFR) (3/6), cyclin-dependent kinase inhibitor 2A (CDKN2A) (3/6), lysine methyltransferase 2D (KMT2D) (3/6), tumor protein p53 (TP53) (3/6), neurofibromin 1 (NF1) (3/6), phosphodiesterase 4D interacting protein (PDE4DIP) (3/6), cytochrome P450 family 2 subfamily D member 6 (CYP2D6) (2/6), fms-related receptor tyrosine kinase 4 (FLT4) (2/6) and myosin heavy chain 9 (MYH9) (2/6). Of the two cases analyzed in the papilloma-oncology carcinoma pair, one did not have any common mutations; the other showed a staged functional deletion of TP53 during the process of malignant transformation from SNIP to SCC. Conclusion CDKN2A, KMT2D, NF1, PDE4DIP, CYP2D6, FLT4, and MYH9 were identified as candidate novel SNIP-derived SCC-related genes.
- Published
- 2020
28. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas
- Author
-
Ryuji Yasumatsu, Rina Jiromaru, Hidetaka Yamamoto, Takahiro Hongo, Masanobu Sato, Takeshi Iwasaki, Yui Nozaki, and Yoshinao Oda
- Subjects
0301 basic medicine ,Adult ,Male ,endocrine system diseases ,Adolescent ,Thyroid Carcinoma, Anaplastic ,Pathology and Forensic Medicine ,Thyroid carcinoma ,03 medical and health sciences ,BRAF Gene Mutation ,Young Adult ,0302 clinical medicine ,Predictive Value of Tests ,Proto-Oncogene Proteins ,medicine ,ROS1 ,Biomarkers, Tumor ,Humans ,Anaplastic Lymphoma Kinase ,Genetic Predisposition to Disease ,Receptor, trkC ,Thyroid Neoplasms ,Receptor, trkA ,In Situ Hybridization, Fluorescence ,Aged ,Aged, 80 and over ,Gene Rearrangement ,medicine.diagnostic_test ,business.industry ,ALK Gene Rearrangement ,Reproducibility of Results ,Gene rearrangement ,Middle Aged ,Protein-Tyrosine Kinases ,Immunohistochemistry ,ROS1 Gene Rearrangement ,030104 developmental biology ,Phenotype ,Thyroid Cancer, Papillary ,030220 oncology & carcinogenesis ,Cancer research ,Female ,business ,Fluorescence in situ hybridization - Abstract
Summary NTRK1/3, ALK, and ROS1 translocations have been reported in a minor subset of papillary thyroid carcinomas (PTCs). We aimed to elucidate the prevalence and clinicopathological characteristics of these gene rearrangements and the utility of immunohistochemistry (IHC) in PTC and anaplastic thyroid carcinoma (ATC). We screened nonradiation-exposed cases of 307 PTCs and 16 ATCs by IHC for pan-Trk, ALK, and ROS1, followed by fluorescence in situ hybridization (FISH). In the PTC group, IHC for pan-Trk, ALK, and ROS1 was positive in 18 cases (5.9%), 1 case (0.3%), and 12 cases (3.9%), respectively. Among the pan-Trk IHC–positive cases (n = 18), 2 cases (11.1%; 0.7% of all PTCs) had NTRK1 or NTRK3 gene rearrangement with conventional PTC histology. The ALK IHC–positive case (n = 1) was the follicular variant of PTC with consistent ALK gene rearrangement. ROS1 gene rearrangement was not detectable in the ROS1 IHC–positive PTCs (0/12) by FISH. Most (approximately 70%) of the pan-Trk or ROS1 IHC–positive/FISH–negative cases had BRAF gene mutation with conventional PTC morphology. In the ATC group, neither ALK nor ROS1 IHC was positive, whereas pan-Trk IHC was positive in 1 case (6.3%) in which NTRK1 gene rearrangement was confirmed by FISH. These results suggest that NTRK, ALK, and ROS1 rearrangements are rare molecular events in nonradiation-exposed Japanese patients with PTC and ATC. Although IHC is not an entirely specific surrogate for these abnormalities and does not serve as a stand-alone companion diagnosis, the combined use of IHC and molecular testing may be helpful for determining promising therapeutic strategies with tyrosine kinase inhibitors.
- Published
- 2020
29. Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events
- Author
-
Ryuji Yasumatsu, Ryutaro Uchi, Muneyuki Masuda, Tomomi Manako, Mioko Matsuo, Kazuki Hashimoto, Toranoshin Takeuchi, Takashi Nakagawa, Takahiro Wakasaki, and Rina Jiromaru
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Kaplan-Meier Estimate ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Antineoplastic Agents, Immunological ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,030223 otorhinolaryngology ,Head and neck ,Adverse effect ,Complete response ,Aged ,Aged, 80 and over ,business.industry ,Head and neck cancer ,Remission Induction ,General Medicine ,Middle Aged ,medicine.disease ,Disease control ,Discontinuation ,Nivolumab ,Treatment Outcome ,Otorhinolaryngology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Significant immune-related adverse events (irAEs) requiring therapy discontinuation sometimes occur. The influence of discontinuation on disease control after an irAE is unclear.The aim of this study was to investigate whether or not patients continued to show a response or durable disease control even after stopping therapy following an irAE.The response after nivolumab monotherapy discontinuation was examined for 14 patients in whom therapy was stopped without progression.The best response was CR in 5 (36%) patients, PR in 8 (57%) patients and SD in 1 (7%) patient. The estimated 1-year overall and progression-free survival rates were 92.9% and 78.6%, respectively. The best response during nivolumab therapy in patients who developed PD was CR in 0 of 5 patients (0%), PR in 3 of 8 patients (38%) and SD in 1 patient (100%). Patients obtaining CR tended to have a lower risk of PD than those with PR or SD.Patients with CR status may continue to show a response or durable disease control even after stopping therapy due to an irAE.
- Published
- 2020
30. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Author
-
Ryuji Yasumatsu, Mioko Matsuo, Muneyuki Masuda, Ryutaro Uchi, Rina Jiromaru, Toranoshin Takeuchi, Tomomi Manako, Takahiro Wakasaki, Noritaka Komune, Takashi Nakagawa, and Teppei Noda
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,chemotherapy ,head and neck squamous cell carcinoma ,lcsh:RC254-282 ,Article ,C-reactive protein ,03 medical and health sciences ,0302 clinical medicine ,recurrent ,distant metastasis ,Internal medicine ,medicine ,Neutrophil to lymphocyte ratio ,neutrophil to lymphocyte ratio ,nivolumab ,Chemotherapy ,Cetuximab ,biology ,business.industry ,Combination chemotherapy ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Head and neck squamous-cell carcinoma ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,Biomarker (medicine) ,biomarker ,Nivolumab ,business ,medicine.drug - Abstract
Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received S1, an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<, 1.2 mg/dL) or low NLR (<, 7.0) values at the time of SCT induction, which was significantly associated with an improved OS (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR This is the first report on biomarkers of SCT in R/M HNSCC
- Published
- 2020
31. Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab
- Author
-
Ryuji Yasumatsu, Muneyuki Masuda, Kazuki Hashimoto, Rina Jiromaru, Kuniaki Sato, Ryutaro Uchi, Tomomi Manako, Takashi Nakagawa, Takahiro Wakasaki, Satoshi Toh, and Mioko Matsuo
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Cetuximab ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,030223 otorhinolaryngology ,neoplasms ,Retrospective Studies ,Chemotherapy ,business.industry ,Incidence (epidemiology) ,Medical record ,Incidence ,Head and neck cancer ,Interstitial lung disease ,Middle Aged ,medicine.disease ,Head and neck squamous-cell carcinoma ,digestive system diseases ,Nivolumab ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,Oral Surgery ,Neoplasm Recurrence, Local ,business ,Lung Diseases, Interstitial ,medicine.drug - Abstract
Background Drug-induced interstitial lung disease (DI-IP) is one of the most serious adverse reactions associated with the use of anticancer drugs. DI-IP prevalence among molecular-targeting drugs and immune checkpoint inhibitors (ICIs) is relatively high in Japanese patients. To assess the risk of cetuximab and/or nivolumab-related IP is important. Patients and Methods The medical records of 138 patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab-containing chemotherapy and/or nivolumab monotherapy were retrospectively reviewed. Results The incidence of DI-IP with R/M HNSCC was 7.2%. DI-IP occurred more frequently in patients treated with cetuximab-containing chemotherapy following nivolumab monotherapy than in patients with other regimens. However, tumor suppression was detected in all patients treated with cetuximab-containing chemotherapy following nivolumab monotherapy, and two achieved a complete response. Conclusions Although patients treated with cetuximab-containing chemotherapy following nivolumab showed dramatic efficacy, careful monitoring should be recommended.
- Published
- 2020
32. Malignant perivascular epithelioid cell tumor mimicking jugular foramen schwannoma: A case report and literature review
- Author
-
Takashi Nakagawa, Rina Jiromaru, Noritaka Komune, Shogo Masuda, Nozomu Matsumoto, Osamu Akiyama, Nana Tsuchihashi, Hidetaka Yamamoto, Takahiro Hongo, Ryuji Yasumatsu, and Satoshi Matsuo
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Accessory nerve ,Transverse sinuses ,Neurosurgery ,Article ,Perivascular Epithelioid Cell ,03 medical and health sciences ,Skull base tumor ,0302 clinical medicine ,Cancer surgery ,Jugular Foramen Schwannoma ,Jugular foramen ,medicine.artery ,Biopsy ,Ear-Nose-Throat ,Medicine ,PEComa ,lcsh:Social sciences (General) ,lcsh:Science (General) ,Multidisciplinary ,medicine.diagnostic_test ,business.industry ,Skull ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Surgery ,lcsh:H1-99 ,Radiology ,Internal carotid artery ,business ,030217 neurology & neurosurgery ,lcsh:Q1-390 - Abstract
Background Perivascular epithelioid cell tumors (PEComas) of the skull base are extremely rare. Here we report the first description of a malignant PEComa mimicking jugular foramen schwannoma and presenting as Collet-Sicard syndrome, and we review the previous literature on PEComas of the head, neck and skull base. Case description A 29-year-old woman presented with hoarseness, dysphagia, vomiting, and headache. She was first diagnosed with Collet-Sicard syndrome caused by thrombosis of the sigmoid and transverse sinuses. She was treated with anticoagulant therapy, and the hoarseness and paralysis of the accessory nerve improved. Later, at age 31, the hoarseness again worsened. At another hospital, enhanced computed tomography revealed a tumor in the jugular foramen extending to the neck and medially displacing the internal carotid artery. She was referred to our hospital for further examination and was diagnosed with jugular foramen schwannoma causing thrombosis of the sinuses. At the one-year follow-up, the tumor had grown rapidly and had started to surround the internal carotid artery. We therefore performed a tissue biopsy of the tumor in the jugular foramen and neck. Based on pathological analysis, we made a definitive diagnosis of malignant PEComa. Conclusions It may be extremely challenging to reach an accurate diagnosis of PEComa in the skull-base region, which can cause a delay in treatment initiation. When atypical clinical features for a skull-base tumor are found, we recommend preliminary biopsy to obtain a definitive diagnosis and initiate an appropriate treatment strategy as early as possible., Oncology; Surgery; Cancer surgery; Neurosurgery; Ear-Nose-Throat; Jugular foramen; PEComa; Skull base tumor
- Published
- 2020
33. Wnt/β-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland
- Author
-
Masanobu Sato, Ryuji Yasumatsu, Rina Jiromaru, Takashi Nakagawa, Yui Hatanaka, Muneyuki Masuda, Toshimitsu Nishijima, Kenichi Taguchi, Yoshinao Oda, and Hidetaka Yamamoto
- Subjects
Adenoma ,Adult ,Male ,0301 basic medicine ,Adolescent ,Adenoid cystic carcinoma ,Adenomatous Polyposis Coli Protein ,Adenoma, Pleomorphic ,Adenocarcinoma ,Biology ,Basal cell adenoma ,Salivary Glands ,Pathology and Forensic Medicine ,Pleomorphic adenoma ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Axin Protein ,Biomarkers, Tumor ,medicine ,AXIN2 ,Humans ,skin and connective tissue diseases ,Wnt Signaling Pathway ,beta Catenin ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,Wnt signaling pathway ,Cell Biology ,Middle Aged ,Salivary Gland Neoplasms ,medicine.disease ,Carcinoma, Adenoid Cystic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Catenin ,Mutation ,Cancer research ,Immunohistochemistry ,Female ,Fluorescence in situ hybridization - Abstract
Differential diagnosis among basal cell adenoma (BCA), basal cell adenocarcinoma (BCAC), adenoid cystic carcinoma (ACC) and pleomorphic adenoma (PA) of the salivary gland can be challenging due to their similar histological appearance. Although frequent nuclear β-catenin expression and CTNNB1 mutations have been reported in BCA, further details of the Wnt/β-catenin signal alterations are unclear. The aim of this study was to assess the diagnostic utility of Wnt/β-catenin signal alteration in BCA and morphological mimics. We performed immunohistochemical staining for β-catenin and mutation analysis for Wnt/β-catenin-related genes (CTNNB1, APC, AXIN1 and AXIN2) in BCA (n = 34), BCAC (n = 3), ACC (n = 67) and PA (n = 31). We also analyzed ACC-specific MYB and MYBL1 gene rearrangements by fluorescence in situ hybridization (FISH). Nuclear β-catenin expression (≥3%) was present in 32/34 cases (94.1%) of BCA, and the nuclear β-catenin labeling index was significantly higher than in other tumor types (p = 0.0001). In BCA, we found mutations in CTNNB1, APC and AXIN1 genes (41.1%, 2.9% and 8.8%, respectively). In BCAC, nuclear β-catenin expression with CTNNB1 mutation was present in 1/3 cases (33.3%). As for ACC, nuclear β-catenin expression was observed in 3/67 cases (4.4%), but all 3 cases harbored either MYB or MYBL1 gene rearrangement. The results suggest that nuclear β-catenin immunoreactivity with appropriate criteria may be helpful to distinguish BCA from histologically similar tumors. However, a minor subset of ACCs with nuclear β-catenin expression require careful diagnosis. In addition, Wnt/β-catenin signal alteration may play a role in the pathogenesis of BCA and BCAC.
- Published
- 2018
34. Genetic and transcriptomic analyses in a rare case of human papillomavirus–related oropharyngeal squamous-cell carcinoma combined with small-cell carcinoma
- Author
-
Kenichi Taguchi, Hidetaka Yamamoto, Kuniaki Sato, Shinya Oda, Yuichiro Higaki, Rina Jiromaru, Takashi Nakagawa, Fumihide Rikimaru, Akihide Matsunaga, Muneyuki Masuda, Satoshi Toh, Kazuo Nishiyama, and Ryozaburo Nagata
- Subjects
Research Report ,Papillomavirus Infections ,General Medicine ,Alphapapillomavirus ,Biology ,medicine.disease ,Malignancy ,Immunohistochemistry ,Neuroendocrine differentiation ,Small-cell carcinoma ,Transcriptome ,Oropharyngeal Carcinoma ,Carcinoma, Squamous Cell ,Carcinoma ,medicine ,Cancer research ,Humans ,Gene ,neoplasia of the pharynx ,Exome sequencing - Abstract
Human papillomavirus (HPV)-related oropharyngeal small-cell carcinoma (OPSmCC) is a rare malignancy with aggressive behavior, whereas HPV-related oropharyngeal squamous-cell carcinoma (OPSqCC) displays a favorable prognosis. Notably, these two malignancies occasionally arise in an identical tumor. In this case study, we explored the molecular characteristics that distinguishes these two carcinomas using a rare case of HPV-related oropharyngeal carcinoma (OPC) with the combined histology of SmCC and SqCC. Immunohistochemical analysis and HPV-RNA in situ hybridization (ISH) suggested that both SmCC and SqCC were HPV-related malignancies. Targeted exome sequencing revealed that SmCC and SqCC had no significant difference in mutations of known driver genes. In contrast, RNA sequencing followed by bioinformatic analyses suggested that aberrant transcriptional programs may be responsible for the neuroendocrine differentiation of HPV-related OPC. Compared to SqCC, genes up-regulated in SmCC were functionally enriched in inflammatory and immune responses (e.g., arachidonic acid metabolism). We then developed a SmCC-like gene module (top 10 up-regulated genes) and found that OPC patients with high module activity showed poor prognosis in The Cancer Genome Atlas (TCGA) and GSE65858 cohort. Gene set enrichment analysis of the SmCC-like gene module suggested its link to MYC proto-oncogene in the TCGA data set. Taken together, these findings suggest that the SmCC-like gene module may contribute to acquisition of aggressive phenotypes and tumor heterogeneity of HPV-related OPC. The present case study is the first report of genetic and transcriptomic aberrations in HPV-related OPSmCC combined with SqCC.
- Published
- 2021
35. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
- Author
-
MIOKO MATSUO, RYUJI YASUMATSU, MUNEYUKI MASUDA, SATOSHI TOH, TAKAHIRO WAKASAKI, KAZUKI HASHIMOTO, RINA JIROMARU, TOMOMI MANAKO, and TAKASHI NAKAGAWA
- Subjects
SQUAMOUS cell carcinoma ,NIVOLUMAB ,HEAD & neck cancer treatment ,BIOMARKERS ,C-reactive protein ,OVERALL survival - Abstract
Background/Aim: The inflammation-based prognostic score (IBPS) has attracted attention recently as a prognostic biomarker for head and neck cancer patients. However, as the IBPS often changes after anticancer drug therapy, its independent prognostic value remains controversial. We aimed to investigate the relationship between the IBPS and prognosis in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with nivolumab, and investigate changes in the IBPS before and after nivolumab treatment. Patients and Methods: Total of 164 patients with RMHNSCC received nivolumab therapy were retrospectively analyzed. Results: Univariate analysis among the 164 patients revealed that the performance status (PS), immune-related adverse event (irAE) status, pre- and post-therapy Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), plateletto- lymphocyte ratio (PLR), and post-eosinophil count, were all significant predictors of overall survival (OS) (p<0.05). A multivariate analysis revealed that PS, irAEs, post-GPS, post-NLR, post-CAR, and post-eosinophil count were independent prognostic factors for overall survival. Conclusion: Post-treatment factors were identified as independent prognostic factors for RMHNSCC and can more accurately predict prognosis compared to nivolumab-treated RMHNSCC pre-treatment factors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Clinical Management of Early-Stage Hypopharyngeal Squamous Cell Carcinoma: A Single-Institution Clinical Analysis
- Author
-
Tomomi Manako, Takahiro Wakasaki, Kazuki Hashimoto, Rina Jiromaru, Mioko Matsuo, Ryuji Yasumatsu, and Takashi Nakagawa
- Subjects
medicine.medical_specialty ,Clinical pathology ,business.industry ,High resolution ,Early detection ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Hypopharyngeal squamous cell carcinoma ,medicine ,Radiology ,Single institution ,Detection rate ,Esophagus ,Stage (cooking) ,030223 otorhinolaryngology ,business - Abstract
Objective: Early detection of hypopharyngeal squamous cell carcinoma (SCC) is important for both an improved prognosis and less-invasive treatment. We retrospectively analyzed the detection rates of early hypopharyngeal SCCs according to the evaluation methods and the clinical management of early hypopharyngeal SCCs. Methods: Sixty-eight patients with early hypopharyngeal SCC who were diagnosed were reviewed. Results: The number of early hypopharyngeal cancer patients with asymptomatic or synchronous or metachronous esophageal cancer examined by upper gastrointestinal endoscopy with narrow-band imaging (NBI) was significantly higher than those examined by laryngopharyngeal endoscopy with NBI. The 3-year disease-specific survival rates according to T classification were as follows: Tis, 100%; T1, 100%; T2, 79.8%; and overall, 91.2%, respectively. Conclusions: Early-stage hypopharyngeal SCC can be cured by minimally invasive transoral surgery or radiotherapy. Observation of the pharynx using NBI in patients with a history of head and neck cancer, esophageal cancer, gastric cancer, or pharyngeal discomfort is very important, and routinely examining the pharynx with NBI, even in patients undergoing endoscopy for screening purposes, is recommended.
- Published
- 2021
37. A case of hypopharynx and esophageal carcinoma with brain metastasis at initial diagnosis
- Author
-
Rina Jiromaru and Mioko Matuo
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Carcinoma ,medicine ,medicine.disease ,business ,Brain metastasis - Published
- 2017
38. A case of therapy-related myelodysplastic syndrome after oral cancer therapy
- Author
-
Mioko Matsuo and Rina Jiromaru
- Subjects
Oncology ,medicine.medical_specialty ,Otorhinolaryngology ,business.industry ,Internal medicine ,medicine ,Cancer therapy ,business ,Therapy-related myelodysplastic syndrome - Published
- 2017
39. Genetic and transcriptomic analyses in a rare case of human papillomavirus-related oropharyngeal squamous-cell carcinoma combined with small-cell carcinoma.
- Author
-
Kuniaki Sato, Kazuo Nishiyama, Kenichi Taguchi, Rina Jiromaru, Hidetaka Yamamoto, Akihide Matsunaga, Ryozaburo Nagata, Fumihide Rikimaru, Satoshi Toh, Yuichiro Higaki, Shinya Oda, Takashi Nakagawa, and Muneyuki Masuda
- Subjects
TRANSCRIPTOMES ,PAPILLOMAVIRUSES ,SQUAMOUS cell carcinoma ,OROPHARYNGEAL cancer ,IN situ hybridization - Abstract
Human papillomavirus (HPV)-related oropharyngeal small-cell carcinoma (OPSmCC) is a rare malignancy with aggressive behavior, whereas HPV-related oropharyngeal squamous-cell carcinoma (OPSqCC) displays a favorable prognosis. Notably, these two malignancies occasionally arise in an identical tumor. In this case study, we explored the molecular characteristics that distinguishes these two carcinomas using a rare case of HPV-related oropharyngeal carcinoma (OPC) with the combined histology of SmCC and SqCC. Immunohistochemical analysis and HPV-RNA in situ hybridization (ISH) suggested that both SmCC and SqCC were HPV-related malignancies. Targeted exome sequencing revealed that SmCC and SqCC had no significant difference in mutations of known driver genes. In contrast, RNA sequencing followed by bioinformatic analyses suggested that aberrant transcriptional programs may be responsible for the neuroendocrine differentiation of HPV-related OPC. Compared to SqCC, genes up-regulated in SmCC were functionally enriched in inflammatory and immune responses (e.g., arachidonic acid metabolism). We then developed a SmCC-like gene module (top 10 up-regulated genes) and found that OPC patients with high module activity showed poor prognosis in The Cancer Genome Atlas (TCGA) and GSE65858 cohort. Gene set enrichment analysis of the SmCC-like gene module suggested its link to MYC proto-oncogene in the TCGA data set. Taken together, these findings suggest that the SmCC-like gene module may contribute to acquisition of aggressive phenotypes and tumor heterogeneity of HPV-related OPC. The present case study is the first report of genetic and transcriptomic aberrations in HPV-related OPSmCC combined with SqCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.